# ClinicalTrials.gov record NCT02315001

> PeptideScanner retained ClinicalTrials.gov record NCT02315001 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-20, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02315001-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-05-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02315001-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02315001-liraglutide-v1.json
- Content SHA-256: `7133a05b2772d8ac6f11dd2db3d5876ac76968995a8c858587457b5a5122d3b6`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02315001 ([`ctg-observation-nct02315001-2015-05-20-c8b22fe0af35`](#source-ctg-observation-nct02315001-2015-05-20-c8b22fe0af35))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02315001 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-20, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02315001-2015-05-20-c8b22fe0af35`](#source-ctg-observation-nct02315001-2015-05-20-c8b22fe0af35))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02315001 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-20, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02315001-2015-05-20-c8b22fe0af35`](#source-ctg-observation-nct02315001-2015-05-20-c8b22fe0af35))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02315001-2015-05-20-c8b22fe0af35`](#source-ctg-observation-nct02315001-2015-05-20-c8b22fe0af35))

## Sources

<a id="source-ctg-observation-nct02315001-2015-05-20-c8b22fe0af35"></a>
- **ClinicalTrials.gov record NCT02315001 · retained source version 2015-05-20:c8b22fe0af3557d5f12f6c331ba0293f7c849252a4c3b2bae3c173c3fe639190** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02315001) (`ctg-observation-nct02315001-2015-05-20-c8b22fe0af35`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02315001." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02315001-liraglutide-v1.json SHA-256: 7133a05b2772d8ac6f11dd2db3d5876ac76968995a8c858587457b5a5122d3b6.